Deinove has signed a license option agreement with the British compan yRedx Pharma to acquire its anti-infective program, Novel Bacterial Topoisomerase Inhibitor (NBTI), which targets Gram-negative infections.
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals have entered into collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases.
Danish pharma company H. Lundbeck has agreed to acquire Switzerland-based Prexton Therapeutics, which develops drugs for Parkinson's disease and other brain disorders, in a deal worth about DKK6.75bn (€905m).
Zymeworks announced that ZW49 is the first product candidate selected for clinical development using the ZymeLink antibody-drug conjugate (ADC) platform, acquired as part of its 2016 purchase of Kairos Therapeutics.
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).
Biogen has agreed to buy Pfizer's investigational schizophrenia drug, PF-04958242, in a deal worth about $590m.
LabCorp's Covance Drug Development business has established a global immunology and immunotoxicology (I&I) unit to focus on the development of biologic drugs.
Evotec and Sanofi are in exclusive negotiations to create an infectious disease open innovation research and development (R&D) platform through a new open innovation platform near Lyon in France.
Merck has formed an oncology collaboration with Eisai to jointly develop and commercialize the latter's Lenvima cancer treatment both as a monotherapy as well as in combination with its anti-PD-1 therapy, Keytruda, for various types of cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.